Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Bupropion XL in Chinese Healthy Volunteers
NCT02698553Phase 1Completed
- Sponsor
- GSK
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupropion in major depressive disorder (MDD), sponsored by GSK. Primary endpoints: Time to Peak Plasma Concentration, Maximum Observed Plasma Concentration at Day 2 and 4 more. Started May 2016; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02698553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698553.